Page last updated: 2024-12-06
tinopal
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
Tinopal: fluorescent whitening agents or optical brightners; used in detergents; RN given refers to parent cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 5750263 |
SCHEMBL ID | 461641 |
MeSH ID | M0057923 |
Synonyms (14)
Synonym |
---|
(e)-4,4'-bis[(4-anilino-6-morpholino-s-triazin-2-yl)amino]-2,2'-stilbenedisulfonic acid |
tinopal |
4,4'-bis((4-anilino-6-morpholino-1,3,5-triazin-2-yl)amino)stilbene-2,2'-disulphonic acid |
einecs 246-097-5 |
benzenesulfonic acid, 2,2'-(1,2-ethenediyl)bis(5-((4-(4-morpholinyl)-6-(phenylamino)-1,3,5-triazin-2-yl)amino)- |
(e)-4,4'-bis((4-anilino-6-morpholino-s-triazin-2-yl)amino)-2,2'-stilbenedisulfonic acid |
32466-46-9 |
2,2'-stilbenedisulfonic acid, 4,4'-bis((4-anilino-6-morpholino-s-triazin-2-yl)amino)-, (e)- |
benzenesulfonic acid, 2,2'-(1,2-ethenediyl)bis[5-[[4-(4-morpholinyl)-6-(phenylamino)-1,3,5-triazin-2-yl]amino]- |
SCHEMBL461641 |
(e)-6,6'-(ethene-1,2-diyl)bis(3-((4-morpholino-6-(phenylamino)-1,3,5-triazin-2-yl)amino)benzenesulfonic acid) |
DTXSID40892587 |
2,2'-[(e)-1,2-ethenediyl]bis(5-{[4-anilino-6-(4-morpholinyl)-1,3,5-triazin-2-yl]amino}benzenesulfonic acid) |
(e)-6,6'-(ethene-1,2-diyl)bis(3-((4-morpholino-6-(phenylamino)-1,3,5-triazin-2-yl)amino)benzenesulfonicacid) |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (11)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (9.09) | 18.7374 |
1990's | 2 (18.18) | 18.2507 |
2000's | 7 (63.64) | 29.6817 |
2010's | 1 (9.09) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 1 (9.09%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 10 (90.91%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |